StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eisai And Biogen (BIIB) to Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
September 13, 2019 8:00 AM
(Updated - September 13, 2019 8:01 AM EDT)Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced the decision to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Next Articles
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
September 13, 2019 8:00 AM